FAQs of Lipo-Mino-Mix-C: What exactly is Lipo-Mino-Mix-C and what does it contain
After at least two years of treatment, GLP-1 users had a 37 percent higher chance of developing alopecia than patients taking SGLT-2 drugs and 68 percent higher odds than those taking DPP-4 drugs, both of which are also used to treat type 2 diabetes
McLaughlin breaks down who may qualify for GLP-1 therapy You may be a candidate if you have: BMI 30 (obesity), or BMI 27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) Type 2 diabetes or prediabetes Insulin resistance or metabolic syndrome Cardiovascular risk factors where weight loss would improve outcomes GLP-1s are typically not approved for patients with: Personal or family history of medullary thyroid cancer or MEN2 Prior severe pancreatitis linked to GLP-1 use Significant untreated GI disorders or eating disorders Approval may also depend on insurance requirements, documented lifestyle attempts, and whether the prescription is for diabetes vs
For many patients, the idea of an injection feels less intimidating than surgery, even if the results are more modest
Below is an example dose conversion: Regardless of which treatment you are switching from, the change should always be done under clinical supervision
Reducing glucagon secretion
